Biomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002, Cadiz, Spain.
Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11002, Cadiz, Spain.
Mol Med. 2022 Apr 9;28(1):40. doi: 10.1186/s10020-022-00465-w.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already caused 6 million deaths worldwide. While asymptomatic individuals are responsible of many potential transmissions, the difficulty to identify and isolate them at the high peak of infection constitutes still a real challenge. Moreover, SARS-CoV-2 provokes severe vascular damage and thromboembolic events in critical COVID-19 patients, deriving in many related deaths and long-hauler symptoms. Understanding how these processes are triggered as well as the potential long-term sequelae, even in asymptomatic individuals, becomes essential.
We have evaluated, by application of a proteomics-based quantitative approach, the effect of serum from COVID-19 asymptomatic individuals over circulating angiogenic cells (CACs). Healthy CACs were incubated ex-vivo with the serum of either COVID-19 negative (PCR -/IgG -, n:8) or COVID-19 positive asymptomatic donors, at different infective stages: PCR +/IgG - (n:8) and PCR -/IgG + (n:8). Also, a label free quantitative approach was applied to identify and quantify protein differences between these serums. Finally, machine learning algorithms were applied to validate the differential protein patterns in CACs.
Our results confirmed that SARS-CoV-2 promotes changes at the protein level in the serum of infected asymptomatic individuals, mainly correlated with altered coagulation and inflammatory processes (Fibrinogen, Von Willebrand Factor, Thrombospondin-1). At the cellular level, proteins like ICAM-1, TLR2 or Ezrin/Radixin were only up-regulated in CACs treated with the serum of asymptomatic patients at the highest peak of infection (PCR + /IgG -), but not with the serum of PCR -/IgG + individuals. Several proteins stood out as significantly discriminating markers in CACs in response to PCR or IgG + serums. Many of these proteins particiArticle title: Kindly check and confirm the edit made in the article title.pate in the initial endothelial response against the virus.
The ex vivo incubation of CACs with the serum of asymptomatic COVID-19 donors at different stages of infection promoted protein changes representative of the endothelial dysfunction and inflammatory response after viral infection, together with activation of the coagulation process. The current approach constitutes an optimal model to study the response of vascular cells to SARS-CoV-2 infection, and an alternative platform to test potential inhibitors targeting either the virus entry pathway or the immune responses following SARS-CoV-2 infection.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)已在全球范围内导致 600 万人死亡。虽然无症状个体是许多潜在传播的原因,但在感染高峰期识别和隔离他们仍然是一个真正的挑战。此外,SARS-CoV-2 在重症 COVID-19 患者中引起严重的血管损伤和血栓栓塞事件,导致许多相关死亡和长期后遗症。了解这些过程是如何引发的,以及无症状个体中可能存在的长期后果,变得至关重要。
我们通过应用基于蛋白质组学的定量方法,评估了 COVID-19 无症状个体的血清对循环血管生成细胞(CACs)的影响。健康的 CACs 在体外与 COVID-19 阴性(PCR-/IgG-,n:8)或 COVID-19 阳性无症状供体的血清孵育,处于不同的感染阶段:PCR+/IgG-(n:8)和 PCR-/IgG+(n:8)。此外,还应用无标记定量方法来鉴定和定量这些血清之间的蛋白质差异。最后,应用机器学习算法验证 CACs 中的差异蛋白模式。
我们的结果证实,SARS-CoV-2 可在感染无症状个体的血清中引起蛋白质水平的改变,主要与凝血和炎症过程的改变相关(纤维蛋白原、血管性血友病因子、血小板反应蛋白 1)。在细胞水平上,只有在感染的最高高峰期,用无症状患者的血清处理 CACs 时,ICAM-1、TLR2 或 Ezrin/Radixin 等蛋白质才会上调,但用 PCR-/IgG+个体的血清处理则不会。在对 PCR 或 IgG+血清做出反应的 CACs 中,有几种蛋白质作为显著的区分标志物脱颖而出。这些蛋白质中的许多参与了病毒感染后的初始内皮反应。
在不同感染阶段,用无症状 COVID-19 供体的血清体外孵育 CACs,促进了代表病毒感染后内皮功能障碍和炎症反应以及凝血过程激活的蛋白质变化。目前的方法构成了研究血管细胞对 SARS-CoV-2 感染反应的理想模型,也是测试针对 SARS-CoV-2 感染后病毒进入途径或免疫反应的潜在抑制剂的替代平台。